The Integrative Scale as an innovative method to increase the effectiveness of the Program for Providing Certain Categories of Citizens with Necessary Medicines

Evaluation of the effectiveness of Preferential Medicinal Providing is due to the need for rational pharmacotherapy for patients from certain categories of citizens. There are not enough technologies for such an assessment, which requires their creation and implementation.

The purpose of the study. To develop the Integrative Scale for Evaluating the Effectiveness of the Program for Providing Certain Categories of Citizens with the Necessary Medicines on the model of the Far Eastern Federal District as an informative way to establish the effectiveness of the preferential segment of medicinal providing, to show the advantages of this Scale compared to other methods and to propose a set of measures to improve the effectiveness of the Program.

Materials and methods. The results of the patient survey, compliance of the structure of purchased medicines with the regulatory framework and clinical recommendations of the Ministry of Health of the Russian Federation regulating Preferential Medicinal Providing were analyzed. The structure of the incidence of patients who were initially and repeatedly recognized as disabled.

Results. Based on the analysis of compliance with the most important principles of medicinal providing, a technology for evaluating the effectiveness of the Program has been created that allows the participants of the Preferential Medicinal Providing, doctors, Health care organizers, specialists in the field of medicinal procurement, to carry out rational prescribing and purchase of medicines and it is advisable to allocate financial resources taking into account the priority of vital medicines.

Conclusion. The Integrative Scale will contribute to improving the clinical and economic efficiency of the Program and will make a significant contribution to improving and maintenance the quality of life of patients receiving pharmacotherapy in the preferential segment, both at the level of the subject of the Russian Federation and at the level of the national system of Preferential Medicinal Providing. 

1. Volkova NS, Eryomina OYu. Drug Provisioning for Persons with Disabilities: Theoretical and Practical Issues. Journal of Russian Law. 2018;(11):85–96. (In Russ). doi: 10.12737/art_2018_11_8

2. Telnova EA. Experiment ahead of time: about the Moscow experiment on preferential drug provision. Remedium. 2019;(10):70–5. (In Russ). doi: 10.21518/1561–5936–2019–10–70–75

3. Telnova EA, Zagoruychenko AA. About state regulation in the Russian pharmaceutical market and problems of drug supply. Modern organization of drug supply. 2020;(3):11–20. (In Russ). doi: 10.30809/solo.3.2020.2

4. Khabriev RU, Sukhodolov AP, Spasennikov BA, Bezmelnitsyna LY, Meshkov DO. The decision-making system in the Program of Subsidized Pharmaceutical Provision. Izvestiya Baykal’skogo gosudarstvennogo universiteta = Bulletin of Baikal State University. 2018;28(1):6–11. (In Russ). doi:10.17150/2500–2759.2018.28(1).6–11

5. Stakhovskaya LV, Ivanova GE, Repyev AP. Medical law and the legal basis of medical rehabilitation. PacificMedical Journal. 2015;(1):30–4. (In Russ).

6. Order of the Government of the Russian Federation No. 2406-R of October 12, 2019 (with changes and additions) [Internet]. (In Russ). Доступно по: http://base.garant.ru/72861778/. Ссылка активна на 19.08.2022.

7. Министерство здравоохранения Российской Федерации. Рубрикатор клинических рекомендаций [Электронный ресурс]. [Ministry of Health of Russian Federation. Rubricator of Clinical Recommendations [Internet]. (In Russ).]. Доступно по: http://cr.rosminzdrav.ru/. Ссылка активна на 19.08.2022.

8. Procurement: official website of the Unified Information System in the field of procurement [Internet]. (In Russ). Доступно по: https://zakupki.gov.ru/epz/order/extendedsearch/results.html. Ссылка активна на 19.08.2022.

9. Gaygolnik TV, Demko IV, Bochanova EN, Kraposhina AYu, Gordeeva NV, Solovyova IA. Pharmacoeconomic analysis of cost in terms of maintenance of preferential medicines patients with сhronic obstructive pulmonary disease on the territory of Krasnoyarsk region. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya = PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2016;(2):49–59. (In Russ). doi: 10.17749/2070-4909.2016.9.2.049-059

10. Tolkushin AG, Davydovskaya MV, Yagudina RI. The concept of determining the equilibrium price of innovative drug based on their real value — Value Based Pricing. Remedium. 2017;(12):6–14. (In Russ).

11. Cheberda AE. Drug utilization research. Kachestvennaya klinicheskaya praktika. 2017;(1):42–5. (In Russ).

12. Telnova EA. Extensive Drug Coverage — ONLS Program is 10 years. Vestnik Roszdravnadzora. 2016;(5):143–7. (In Russ).